Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metabolic Assessment Clear all
Completed Phase 2 Interventional

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

NCT00867477
View directory record Official record
Conditions
Gastrointestinal Disease, Esophageal Cancer, Lung Cancer
Interventions
Breathing Test, Respiratory Symptoms Questionnaire, Pet Scan
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 19, 2026, 4:52 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)

NCT07818707
View directory record Official record
Conditions
Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions
Glucagon for Injection (Fresenius Kabi USA), [6,6-2H2] glucose, [13C9, 15N1]-glucagon, [1-13C] glucose, [2-13C] glucose
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Exercise in Treatment Resistant Depression (TRD): A Feasibility Study

NCT01383811
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Moderate Intensity Aerobic Exercise, Wait-list
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 2 Interventional

Assessment of Metabolic Response in Critically Ill Patients With Acute Renal Failure

NCT00179166
View directory record Official record
Conditions
Acute Renal Failure
Interventions
TPN nutritional supplement
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 27, 2010 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

NCT01442831
View directory record Official record
Conditions
Healthy
Interventions
Human ADME
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 19, 2026, 4:52 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NCT07219602
View directory record Official record
Conditions
Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Withdrawn No phase listed Observational

Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding

NCT00216983
View directory record Official record
Conditions
Burns
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 19, 2026, 4:52 PM EDT
Active, not recruiting Phase 1 Interventional

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

NCT00977457
View directory record Official record
Conditions
Prostate Cancer
Interventions
DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymerase chain reaction, diagnostic laboratory biomarker analysis, therapeutic conventional surgery
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

NCT01697930
View directory record Official record
Conditions
Solid Malignancy, Lymphoma
Interventions
[18F] 4-L-Fluoroglutamine (2S,4R)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Recruiting Phase 4 Interventional

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of 21-day Purification Program on Healthy Adults

NCT05877365
View directory record Official record
Conditions
Healthy
Interventions
Standard Process 21-Day Purification Program
Dietary Supplement
Lead sponsor
Standard Process Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 19, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors

NCT07360119
View directory record Official record
Conditions
Periampullary Neoplasms, Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Total Pancreatectomy with Islet Autotransplantation (TPIAT)
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Clinical Utility Trial for the SomaLogic CVD-T2D Test

NCT05237271
View directory record Official record
Conditions
Cardiovascular Diseases, Type 2 Diabetes
Interventions
Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D), Educational Materials on the CVD-T2D and Bundled Metabolic Panel
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 2 Interventional Results available

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

NCT00265200
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases
Interventions
zoledronic acid
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 3 Interventional

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

NCT03710291
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
TRC101, Placebo
Drug
Lead sponsor
Tricida, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Azusa, California • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Not applicable Interventional Results available

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

NCT00746252
View directory record Official record
Conditions
Bipolar Disorder
Interventions
risperidone, aripiprazole
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
7 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 19, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke

NCT00721357
View directory record Official record
Conditions
Stroke
Interventions
Treadmill walking, Magnetic resonance spectroscopy
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 19, 2026, 4:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07732400
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
VV-14303
Genetic
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chandler, Arizona • Lady Lake, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Weight Loss Using a Feedback Device in Obese People With the Metabolic Syndrome

NCT03491930
View directory record Official record
Conditions
Weight Loss, Obesity, Pre-Diabetes, Metabolic Syndrome
Interventions
VA MOVE! Coach app, Telephone Coaching, Standard of Care for weight loss.
Device · Behavioral
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

NCT06855628
View directory record Official record
Conditions
Glioma, GBM
Interventions
[6,6-²H₂]-Glucose
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Geriatric Anorexia Study

NCT04858932
View directory record Official record
Conditions
Healthy
Interventions
Continuous Glucose Monitor, Wrist Actigraphy Device, Food Weight Scale, Smart Body Weight Scale
Device
Lead sponsor
Boston University
Other
Eligibility
65 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

NCT00495014
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GSK376501, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 19, 2026, 4:52 PM EDT
Completed No phase listed Observational

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

NCT00550628
View directory record Official record
Conditions
Colorectal Cancer, Neoplasm of Uncertain Malignant Potential
Interventions
DNA methylation analysis, fluorescence in situ hybridization, gene expression analysis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, biopsy, therapeutic conventional surgery, fludeoxyglucose F 18
Genetic · Other · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

NCT00590564
View directory record Official record
Conditions
Hepatitis C
Interventions
Sho-saiko-to
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 19, 2026, 4:52 PM EDT